Nita L. Seibel, M.D.
Dr. Nita L. Seibel, a board-certified pediatric hematologist-oncologist, is the head of the Pediatric Solid Tumor Therapeutics in the Clinical Investigations Branch (CIB) of the Cancer Therapy and Evaluation Program of the National Cancer Institute.
In this role, she leads the development of CTEP’s extramural pediatric solid tumor therapeutics program, working closely with the Children’s Oncology Group (COG), oversees sarcoma trials in the NCTN, and works within CTEP to prioritize NCTN AYA trials. She is the NCI chair for NCI-COG Pediatric MATCH study, co-chair of the NCI AYA Oncology Working Group, and scientific liaison for the Childhood Cancer Survivor Study (CCSS). Previously serving on the implementation team for the Pediatric Immunotherapy Discovery and Development Network (PI-DDN), a Cancer Moonshot initiative, Dr. Seibel is now a member of the implementation team for the Pediatric Immunotherapy Network (PIN).
Prior to joining CIB, Dr. Seibel served as a faculty member of George Washington University School of Medicine and Public Health and attending physician at Children’s National Hospital for twenty years. She is currently an adjunct clinical professor of pediatrics at George Washington University School of Medicine and Health Sciences, and serves on the Editorial Board for the NCI Physician Data Query (PDQ) Pediatric Board.
Selected Publications
Benedetti DJ, et al. (2024) Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5. Cancer. PMID: 37933882
Benedetti DJ, et al. (2024) Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children’s Oncology Group studies AREN0321 and AREN03B2. Cancer. PMID: 38396300
Parsons DW, et al. (2022) NCI-COG Pediatric MATCH Team. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. Journal of Clinical Oncology. PMID: 35353553
Eckstein OS, et al. (2022) Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. Journal of Clinical Oncology. PMID: 35363510
Sankaran H, et al. (2022) Enrollment of adolescent and young adult patients newly diagnosed with cancer in NCI CTEP-sponsored clinical trials before and after launch of the NCI National Clinical Trials Network. Cancer. PMID: 36089859
Additional links to Scientific Publications
- Dr. Seibel’s ORCID is 0000-0001-6259-7955.